Skip to main content
Caplight Logo









Skopos Bio

Skopos Bio

Private
MelbourneHealthcare & Life Scienceshttps://skoposbio.com

Last Round

Seed

Oct 12, 2026

Total Funding Raised

$8.3M

Momentum

Top 1%

of companies Caplight tracks

Company Overview

Skopos Bio operates in Healthcare & Life Sciences and is based in Melbourne. Its latest recorded funding round was a Seed round in October 2026.

Skopos Bio is a biotechnology company that develops precision radiopharmaceutical therapies to target and treat various types of cancer.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Precision Medicine

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Pricing history

Caplight clients see full MarketPrice™ history and secondary transactions.

Book a demo

For institutional investors. Book with your work email.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

Momentum history

Caplight clients track how buyer interest and sentiment change over time.

Book a demo

For institutional investors. Book with your work email.

Skopos Bio Comparables

Compare Skopos Bio with similar companies based on industry and business-model similarity.

Skopos Bio comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
ARTBIO
83%
Convergent Therapeutics
81%
Radionetics Oncology
79%
Book a demo to see all comparables

For institutional investors. Book with your work email.

Skopos Bio Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
SeedOct 12, 2026
Book a demo to see all funding rounds

For institutional investors. Book with your work email.

Skopos Bio Investors

Notable investors and investment history

Skopos Bio investors
InvestorRounds
YosemiteSeed
TenmileSeed
Tin Alley VenturesSeed

Market signals

Structured signals derived from secondary market and firmographic data.

  • Oct 12, 2026

    $8.4M raised from Tenmile and Yosemite.

Book a demo to see all signals

For institutional investors. Book with your work email.

Skopos Bio Filings

Explore SEC and related filing metadata, where available.

Skopos Bio filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Book a demo

For institutional investors. Book with your work email.

Frequently Asked Questions

Common questions about Skopos Bio's valuation, stock price, and market status.

Is Skopos Bio a public or private company?

Skopos Bio is a private company.

What is the current stock price of Skopos Bio?

Skopos Bio is a private company, so its shares have no public market price. Caplight tracks Skopos Bio's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.

How much is Skopos Bio worth (valuation)?

Valuation information for Skopos Bio is not publicly available.

Can I buy Skopos Bio stock?

Skopos Bio shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.

When was Skopos Bio's last funding round?

Skopos Bio's most recent funding round was Seed on October 12, 2026.

Who are the main investors in Skopos Bio?

Key investors in Skopos Bio include Yosemite, Tenmile, Tin Alley Ventures.

Will Skopos Bio IPO soon?

No public IPO plans have been announced for Skopos Bio.

How can I track Skopos Bio secondary market activity?

Caplight tracks bids, offers, and trades in Skopos Bio's shares on secondary markets.

Firmographic Details

HeadquartersMelbourne
Employee Range7
Year Founded2024
Last FundingOct 12, 2026

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Book a demo

For institutional investors. Book with your work email.

See something wrong or outdated?